Immunization schedule for a fit elderly patient, with evidence-based reasons

Immunization is primary prevention in geriatrics — the aim is to prevent infection-related hospitalisation, functional decline and death, not merely infection.

Immunosenescence makes older adults respond less well to vaccines; hence higher-dose, adjuvanted, conjugate or recombinant preparations are preferred in this age group.

Pathy's recommends tailoring vaccination to the patient's functional category — Fit, Frail, Moderately demented, End of life — and to probable life expectancy. A fit elderly patient receives the complete schedule.

Give annually to all older patients in every category, ideally in early autumn (pre-monsoon / winter in India).

More than 90% of deaths from pneumonia and influenza during epidemics occur in people aged ≥65 years.

Vaccination reduces the risk of influenza by about 50% and influenza-related mortality by about 70%; it also reduces hospitalisation and is cost-effective.

In nursing homes it is only about 40% effective against clinical illness, but is much more effective in preventing pneumonia, hospitalisation and death. Vaccinating >80% of residents prevents outbreaks.

Adjuvanted influenza vaccine is especially valuable in institutionalised elderly and those with diabetes, heart failure or respiratory failure.

Vaccinate healthcare staff and close family contacts — this reduces respiratory infection and mortality among the elderly they care for ("cocooning").

Textbook schedule: one dose PCV13 followed by PPSV23 one year later, after age 65. If PPSV23 was already given, only PCV13 is needed. Pathy's states there is no recommendation on re-immunisation; other tables quote a repeat every 3–5 years.

Antibody response is weaker than in young adults, but the vaccine still reduces invasive pneumococcal disease and pneumococcal bacteraemia in high-risk elders.

CAPITA trial (community-dwelling >65 years): PCV13 reduced vaccine-type pneumococcal pneumonia by 45%. A large Japanese nursing-home RCT showed PPSV23 reduced pneumonia incidence and mortality.

Pneumococcal plus annual influenza vaccine should be offered to all patients with COPD.

Over half of all tetanus cases occur in people aged ≥60 years — a strong argument for boosters in the elderly.

Td booster every 10 years (every 5 years for a tetanus-prone wound). If the primary series is absent or uncertain: 0.5 mL Td IM at 0, 2 months and 6 months. At least one dose should be given as Tdap if never received.

Herpes zoster occurs in up to half of individuals aged ≥85 years; post-herpetic neuralgia affects >40% of those over 60.

Zostavax (live, 2006) is only 30% protective; Shingrix (recombinant, 2016) is ~90% protective. Give 2 doses of Shingrix to all adults ≥50 years, regardless of past chickenpox and even if Zostavax was received earlier.

SARS-CoV-2 vaccines reduce severe disease and mortality; indicated for adults >65 years, healthcare professionals and family members in contact with older individuals.

No vaccine is used for tuberculosis in the elderly — isoniazid 300 mg/day for 9–12 months is given for skin-test converters in selected residents. Tuberculin reaction may be falsely negative due to anergy.

The textbook records two controversies: ecological data showing rising influenza/pneumonia hospitalisation despite rising vaccine uptake (Simonsen et al.), and continuing debate on the cost-effectiveness of pneumococcal vaccine.

RSV vaccine — the biggest addition to the elderly schedule. ACIP now recommends a single dose of Arexvy, Abrysvo or mResvia for unvaccinated adults; additional doses are not currently recommended. Vaccination is universal at ≥75 years and risk-based at 60–74 years; in April 2025 ACIP extended the risk-based recommendation down to 50– 59 years for those at increased risk of severe RSV disease (CDC/ACIP, 2023–2025). Evidence: AReSVi-006 showed 82.6% efficacy against RSV lower respiratory tract disease in adults ≥60, and 94.6% in those with at least one underlying condition; cumulative efficacy over three seasons was 62.9%, with 67.4% against severe RSV-LRTD, falling to 48% in the third season (Lancet Respiratory Medicine, 2025).

Pneumococcal schedule simplified to a single dose. ACIP issued recommendations for the 21-valent pneumococcal conjugate vaccine (PCV21) in adults in 2024, and adults who previously completed PCV13 + PPSV23 after age 65 may receive one dose of PCV20 or PCV21, or no further vaccine. The sequential PCV13 → PPSV23 pathway is being replaced by one dose of PCV20 or PCV21 (MMWR, 2024–2025).

Influenza — product preference and the DANFLU-2 result. For age ≥65, HD-IIV3, RIV3 or aIIV3 is preferred; any age-appropriate vaccine may be used if these are unavailable (CDC Adult Immunization Schedule, 2025–26). However, DANFLU-2, the largest randomised influenza vaccine trial ever conducted, found that high-dose vaccine did not significantly reduce hospitalisation for influenza or pneumonia compared with standard dose (NEJM, December 2025). A prespecified secondary analysis of 332,438 adults ≥65 showed cardiorespiratory hospitalisation of 2.25% with high-dose versus 2.38% with standard dose, driven mainly by fewer cardiovascular hospitalisations (1.30% vs 1.40%) (JAMA Cardiology, 2025).

Zoster vaccine and dementia — a major new off-target signal. A Welsh natural experiment using a date-of-birth eligibility cut-off found that live zoster vaccination reduced new dementia diagnoses by about one-fifth over 7 years (Nature, 2025). A follow-up showed reduced mild cognitive impairment and fewer dementia deaths among those already living with dementia (Cell, 2025). AS01-adjuvanted shingles and RSV vaccines were also associated with reduced 18-month dementia risk in 436,788 matched individuals (npj Vaccines, 2025). Zoster vaccination has additionally been linked to a 23% lower risk of cardiovascular events including stroke, heart failure and coronary heart disease (European Heart Journal, 2025).

COVID-19 policy has shifted. For the 2025–26 season ACIP moved COVID-19 vaccination from a universal recommendation to shared clinical decision-making, with an annually updated formulation (MMWR, 2025).

India — API Consensus Guidelines (essential for the Indian viva). The Association of Physicians of India, with other societies, released an exhaustive adult immunization consensus guideline in 2024, emphasising "bridging childhood vaccines" in adult care. The 2026 Update involves 23 national and regional associations and adopts a life-course immunization framework based on age bands and risk profiles rather than disease category. Key India-specific changes: PCV20 included as the preferred single-dose option, replacing sequential PCV13 → PPSV23 RZV for all adults ≥50 years irrespective of prior shingles, and for immunocompromised adults ≥18 years (cancer, CKD, CVD, transplant, biologics), as 2 doses 2–6 months apart Annual influenza vaccination for all adults over 50, framed as chronic-disease risk reduction, not just seasonal protection Standardised adult immunization cards with written records and linkage to electronic health records HPV positioned as preventive oncology, gender-neutral, with a 3-dose schedule in older and immunocompromised adults Practical Indian note Adult vaccines are not part of the Universal Immunization Programme or NPHCE; they remain largely out-of-pocket, which is the single biggest barrier to uptake.